A Prospective Observational Safety Study in Patients With Advanced Prostate Cancer Treated With Firmagon (Degarelix) on a GnRH Agonist
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 29 Aug 2016
At a glance
- Drugs Degarelix (Primary) ; LHRH receptor agonists
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Ferring Pharmaceuticals
- 28 Jan 2015 Planned End Date changed from 1 Dec 2017 to 1 May 2018 according to ClinicalTrials.gov record.
- 22 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 29 Aug 2012 New source identified and integrated (German Clinical Trials Register; DRKS00004100).